Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that it will present two e-posters at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) taking place 3-5 February 2021.
In addition, the Company will present data on its gene therapy programmes for Gaucher and Fabry Disease, in one oral platform presentation and three e-posters at the 17TH Annual WORLDSymposiumTM taking place 8-12 February 2021.
EAHAD Presentation Details
Title: Follow-up on a Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieving Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)
Presenter: Pratima Chowdary, Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, University College London
Presentation #: ABS-114
Date and Time: Tuesday, 2 February 2021, 6:00 CET
Title: Insight into the Persistent Clinical Burden Underlying Problem Joints, Pain, and Bleeding in Adults from Across Europe with Haemophilia A and B: The CHESS II Study
Presenter: Sharmila Kar, Head of Real-World Evidence, Freeline
Presentation #: ABS-134
Date: Tuesday, 2 February 2021, 6:00 CET
The e-poster presentations will be available from Tuesday, 2 February 2021, as recordings on the events section of the Freeline website.
WORLDSymposiumTM Presentation Details
Platform presentation:
Title: FLT201: An AAV-Mediated Gene Therapy for Type 1 Gaucher Disease Designed to Target Difficult to Reach Tissues
Author: Romuald Corbau, Chief Scientific Officer, Freeline
Date and Time: Thursday, 11 February 2021, 11:36am EST
Poster presentations:
Title: FLT201: An AAV-Mediated Gene Therapy for Type 1 Gaucher Disease Designed to Target Difficult to Reach Tissues
Author: Romuald Corbau, Chief Scientific Officer, Freeline
Presentation #: 44
Date: Thursday, 11 February 2021
Title: Generation of β-Glucocerebrosidase Variants with Increased Half-Life in Human Plasma for Liver Directed AAV Gene Therapy Aimed at the Treatment of Type 1 Gaucher Disease
Author: Fabrizio Comper, Scientific Director, Freeline
Presentation #: 41
Date: Thursday, 11 February 2021
Title: Development of a GLA nAb Assay with a Fully-Human, Neutralizing IgG4 Positive Control to Characterize Antibody Response in Fabry Disease Patients
Author: Sujata Ravi, Scientist, Freeline
Presentation #: 211
Date: Thursday, 11 February 2021
The poster presentations will be available on the events section of the Freeline website from 2:30 pm EST on Monday, 8 February 2021. A recording of the platform presentation with a live Q&A will be available after the presentation concludes on Thursday, 11 February 2021, also on the events section of the Freeline website.